Stargardt Disease clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
ALK-001 on Stargardt Disease
open to eligible people ages 8-70
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
at UCLA
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
at UCLA
Our lead scientists for Stargardt Disease research studies include Michael Gorin, MD, PhD.
Last updated: